Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Stock Has Consensus Target Price of $7.67

Key Points

• Polaryx Therapeutics has a “Moderate Buy” consensus rating from five analysts, with two buy ratings, one strong-buy, one hold, and one sell. The average 12-month price target is $7.67.
• PLYX opened at $1.82, with a $90.73 million market capitalization and a 52-week range of $1.75 to $48.91; its 50-day and 200-day moving averages were $2.04 and $3.18, respectively.
• The clinical-stage biotechnology company reported a quarterly loss of $0.03 per share, beating the $0.05-loss consensus estimate, while analysts expect a full-year loss of approximately $0.22 per share.

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $7.67.

Several research analysts recently weighed in on the stock. Weiss Ratings restated a "sell (e)" rating on shares of Polaryx Therapeutics in a research report on Monday, September 28th. Wall Street Zen upgraded shares of Polaryx Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th. HC Wainwright began coverage on shares of Polaryx Therapeutics in a research note on Thursday, July 9th. They issued a "buy" rating and a $7.00 price target for the company. Zacks Research upgraded shares of Polaryx Therapeutics to a "hold" rating in a research report on Friday, July 10th. Finally, Raymond James Financial assumed coverage on shares of Polaryx Therapeutics in a report on Thursday, August 13th. They issued a "strong-buy" rating and a $6.00 price objective for the company.

Polaryx Therapeutics Stock Down 1.6%

Polaryx Therapeutics stock opened at $1.82 on Tuesday. The stock has a market cap of $90.73 million and a price-to-earnings ratio of -22.75. The business has a 50-day simple moving average of $2.04 and a 200 day simple moving average of $3.18. Polaryx Therapeutics has a 52 week low of $1.75 and a 52 week high of $48.91.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02. On average, research analysts anticipate that Polaryx Therapeutics will post -0.22 earnings per share for the current year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.